tradingkey.logo

Metabolics Pharma Announces Ent-03 Generates Sustained Weight Loss And Liver Pathology Improvements In An Animal Model For Obesity

ReutersJun 27, 2025 4:04 PM

-

  • METABOLICS PHARMA ANNOUNCES ENT-03 GENERATES SUSTAINED WEIGHT LOSS AND LIVER PATHOLOGY IMPROVEMENTS IN AN ANIMAL MODEL FOR OBESITY

  • METABOLICS PHARMA - A PHASE 1B CLINICAL TRIAL IS PLANNED TO INITIATE IN SECOND HALF OF 2025

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI